Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the COVID-19 vaccine Comirnaty, slipped in the U.S. Soaring international sales of the preventive shots helped pushed total Comirnaty revenue close to $13 billion in the quarter, and the drugmaker said Tuesday that it now expects to book about $36 billion in sales from the vaccine this year
Related posts
-
As Schakowsky decision looms, another Democrat announces run for her seat
With veteran Democratic U.S. Rep. Jan Schakowsky expected to announce Monday if she’ll run for reelection... -
Accident in stands puts somber tone on Cubs’ loss to Pirates
During the Cubs’ 4-3 lost at Pittsburgh on Wednesday, the game was delayed several minutes when... -
After restoration, former library reopens as the Waukegan History Museum at the Carnegie
After years of planning and millions in renovations, the meticulously restored, revived and repurposed former Carnegie...